<DOC>
	<DOC>NCT01696045</DOC>
	<brief_summary>The purpose of the study is to comply with the Pediatric Investigation Plan requirements of Ipilimumab</brief_summary>
	<brief_title>Phase 2 Study of Ipilimumab in Children and Adolescents (12 to &lt; 18 Years) With Previously Treated or Untreated, Unresectable Stage III or Stage lV Malignant Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. 12 &lt; 18 years of age Previously treated or untreated, unresectable Stage III or Stage IV malignant melanoma Karnofsky Performance Status (KPS) or Lansky Score â‰¥ 50 Primary Ocular Melanoma Prior therapy with a Cytotoxic T Lymphocyte Antigen 4 (CTLA4) or Programmed death 1 (PD1) antagonist, or Programmed cell death ligand 1 (PDL1) or CD137 agonists Symptomatic brain metastases History of autoimmune diseases</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>